Skip to content

StagingTesting mode — staging environment. No real money: balances, trades, and accounts are for testing only and may be reset at any time.DEMODemo mode: simulated data, for showcase only

Trending New All Live Politics Sports Culture Crypto Economics Companies Climate Tech & Science World Media

Trending New All

Live Politics Sports Culture Crypto Economics Companies Climate Tech & Science World Media

FDA approves Novo's CagriSema in 2026? | Drazill

Tech & Science·Health & Biotech

FDA approves Novo's CagriSema in 2026?

Price and outcomes

FDA approves Novo's CagriSema in 2026?

64¢64¢

36¢36¢

About This Market

Novo Nordisk has filed CagriSema (cagrilintide + semaglutide) for chronic weight management. Resolves YES if the FDA grants approval on or before Dec 31, 2026. Source: FDA / Novo Nordisk.

Quality scoreNot yet rated

Source

Official announcement or authoritative source

Activity and discussion

No comments yet

Sign in to join the discussion on this market.

FDA approves Novo's CagriSema in 2026?

Amount

Slide to Buy YES